Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2833)	7/12/2010 3:31:25 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

SOMX was up 17.12% at its intraday H at 1:50pm and it is still up 11.54% on volume now close to 4M >2x its ADV bigcharts.marketwatch.com SOMX dipped under $4 on June 29 and continue to drift down below $3 on July 7 bigcharts.marketwatch.com That's below where the stock traded in March before its insomnia drug Silenor received FDA approval. <g> The problem is that although SOMX has NLTD and pretty good institutional following,and has been trimming its loss in the last 4Qs, it will need a partner or cash infusion to be able to launch Silenor.<g> The ACTAY has been cut to $10.50 I would put a TT at $5 pending further developments. bigcharts.marketwatch.com Bernard